Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BYSI 
BeyondSpring Inc (BYSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BYSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.25
1 Year Target Price $1.25
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.06% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 76.63M USD | Price to earnings Ratio - | 1Y Target Price 1.25 |
Price to earnings Ratio - | 1Y Target Price 1.25 | ||
Volume (30-day avg) 1 | Beta 0.22 | 52 Weeks Range 0.98 - 3.44 | Updated Date 09/17/2025 |
52 Weeks Range 0.98 - 3.44 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.74% | Return on Equity (TTM) -310.48% |
Valuation
Trailing PE - | Forward PE 10.54 | Enterprise Value 67564408 | Price to Sales(TTM) 31.22 |
Enterprise Value 67564408 | Price to Sales(TTM) 31.22 | ||
Enterprise Value to Revenue 26.53 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 40332300 | Shares Floating 30319015 |
Shares Outstanding 40332300 | Shares Floating 30319015 | ||
Percent Insiders 15.26 | Percent Institutions 14.6 |
Upturn AI SWOT
BeyondSpring Inc
Company Overview
History and Background
BeyondSpring Inc. is a global biopharmaceutical company founded in 2010, focused on developing innovative cancer therapies. It has evolved from early-stage research to late-stage clinical development, with a primary focus on its lead asset, Plinabulin.
Core Business Areas
- Oncology Drug Development: Focuses on the development and commercialization of Plinabulin and other oncology therapies to address unmet medical needs in various cancer types. The company's main drug Plinabulin is being studied in combination with other anti-cancer agents for a broad range of cancer indications.
Leadership and Structure
The leadership team consists of key executives including the CEO, CFO, and Chief Medical Officer. The organizational structure is typical of a biopharmaceutical company, with departments for research and development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Plinabulin: Plinabulin is BeyondSpring's lead drug candidate. It is a selective vasculo-disrupting agent (VDA) and immune-enhancing agent being developed to prevent chemotherapy-induced neutropenia (CIN) and potentially treat various cancers. Competitors in CIN include Neulasta (Amgen) and Granix (Teva).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. It involves the discovery, development, manufacturing, and commercialization of pharmaceutical drugs for various diseases. Significant unmet needs exist for novel cancer therapies, driving innovation and investment in this area.
Positioning
BeyondSpring is positioned as a late-stage biopharmaceutical company focused on oncology. Its competitive advantage lies in Plinabulin's novel mechanism of action and potential to address unmet needs in CIN and cancer treatment. However, its smaller size and limited resources pose challenges against larger, established competitors.
Total Addressable Market (TAM)
The TAM for CIN is estimated to be in the billions of dollars. The overall oncology market is significantly larger. BeyondSpring's position regarding TAM depends on the success of its clinical trials and regulatory approvals for Plinabulin in different indications.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Plinabulin)
- Targeting significant unmet medical needs
- Late-stage clinical development
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on Plinabulin success
- Lack of established commercial infrastructure
- History of regulatory challenges/denials
Opportunities
- Potential regulatory approvals for Plinabulin
- Expansion into new indications
- Strategic partnerships or collaborations
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established players
- Market access and reimbursement challenges
- Patent expirations
Competitors and Market Share
Key Competitors
- AMGN
- TEVA
- SGEN
Competitive Landscape
BeyondSpring faces intense competition from established pharmaceutical companies with larger R&D budgets, commercial infrastructure, and market access. BeyondSpring's success depends on differentiating Plinabulin based on efficacy, safety, and convenience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by clinical development milestones and fundraising activities.
Future Projections: Future growth depends heavily on Plinabulin's regulatory approvals and commercial success. Analyst estimates vary based on the likelihood of approval and market penetration.
Recent Initiatives: Recent initiatives include pursuing regulatory approvals for Plinabulin in the U.S. and China, exploring strategic partnerships, and managing its cash position.
Summary
BeyondSpring is a biopharmaceutical company with a late-stage asset, Plinabulin, targeting unmet needs in oncology, particularly CIN. While the company has the potential for growth, its financial stability, regulatory hurdles, and competition from larger companies pose significant risks. Success hinges on Plinabulin's approval and commercialization and securing additional funding to support its operations. Recent regulatory setbacks and financial constraints require careful monitoring.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry databases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is approximate and may vary based on source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeyondSpring Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2017-03-09 | Co-Founder, Chairman & CEO Dr. Lan Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://beyondspringpharma.com |
Full time employees 40 | Website https://beyondspringpharma.com | ||
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.